Two Sigma Advisers
ATXS

Two Sigma Advisers’s Astria Therapeutics ATXS Stock Holding History

Two Sigma Advisers’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-133,034
Closed -$1.11M – 2385
2023
Q2 		$1.11M Sell
133,034
-40,700
-23% -$470K ﹤0.01% 1490
2023
Q1 		$2.31M Buy
173,734
+94,600
+120% +$1.28M 0.01% 1203
2022
Q4 		$1.18M Buy
+79,134
New +$816K ﹤0.01% 1499
2021
Q3 		– Sell
-6,033
Closed -$76K – 2439
2021
Q2 		$76K Sell
6,033
-8,167
-58% -$106K ﹤0.01% 2362
2021
Q1 		$246K Buy
14,200
+6,900
+95% +$125K ﹤0.01% 2290
2020
Q4 		$94K Buy
7,300
+4,483
+159% +$79.9K ﹤0.01% 2274
2020
Q3 		$105K Buy
+2,817
New +$112K ﹤0.01% 2271

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Two Sigma Advisers's ATXS Position: Q3 2023 in Review

Two Sigma Advisers sold out of Astria Therapeutics (ATXS) in Q3 2023, closing a stake of 133,034 shares — an estimated $1.11M sold.

Two Sigma Advisers first reported a position in ATXS in Q3 2020 and held it in 7 quarters. The position peaked at $2.31M in Q1 2023. 68 funds tracked by Wall St. Rank hold ATXS as of Q3 2023.

  • Two Sigma Advisers reported no remaining Astria Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 133,034 Astria Therapeutics shares in Q3 2023, an estimated $1.11M.
  • Two Sigma Advisers first reported a position in Astria Therapeutics in Q3 2020 and held it in 7 quarters.
  • Two Sigma Advisers's Astria Therapeutics position peaked at $2.31M in Q1 2023.
  • 68 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2023.

Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.